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 Validation of a MEPS/UHPLC-PDA methodology for quantification urinary 
eicosanoids 
 Semi-automatic straightforward sample preparation and extraction was optimized 
 Satisfactory figures of merit of method were obtained ensuring robust results 
 Eicosanoids levels from asthmatic patients are highest than healthy individuals  
 
 
ABSTRACT 
Leukotrienes and prostaglandins are arachidonic acid bioactive derived eicosanoids and 
key mediators of bronchial inflammation and response modulation in the airways 
contributing to the pathophysiology of asthma. 
An easy-to-use ultra-high pressure liquid chromatography (UHPLC)-based strategy was 
developed to characterize biomarkers of lipid peroxidation: leukotrienes E4 (LTE4) and 
B4 (LTB4) and 11β-prostaglandin F2α (11PGF2α), present in urine of asthmatic patients 
(N = 27) and healthy individuals (N = 17). A semi-automatic eVol®-microextraction by 
packed sorbent (MEPS) was used to isolate the target analytes. Several experimental 
parameters with influence on the extraction efficiency and on the chromatographic 
resolution, were evaluated and optimized. The method was fully validated under optimal 
extraction (R-AX sorbent, 3 conditioning-equilibration cycles with 250 µL of ACN-water 
at 0.1% FA, 10 extract-discard cycles of 250 µL of sample at a pH of 5.1, elution with 2 
times 50 µL of MeOH and concentration of the eluate until half of its volume) and 
chromatographic conditions (14-min analysis at a flow rate of 300 µL min-1 in an 
UHPLC-PDA equipped with a BEH C18 column), according to IUPAC guidelines. The 
findings indicated good recoveries (>95%) in addition to excellent extraction efficiency 
(>95%) at three concentration levels (low mid and high) with precision (RSDs) less than 
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11%. The lack-of-fit test, goodness-of-fit test and Mandel’s fitting test, revealed good 
linearity within the concentration range. Good selectivity and sensitivity were achieved 
with a limits of detection ranging from 0.04 µg L-1 for LTB4 to 1.12 µg L-1 for 11PGF2α, 
and limits of quantification from 0.10 µg L-1 for the LTB4 to 2.11 µg L-1 for 11PGF2α. 
The successful application of the fully validated method shows that, on average, the 
asthmatic patients had significantly higher concentrations of 11PGF2α (112.96 µg L-1 vs 
62.56 µg L-1 in normal controls), LTE4 (1.27 µg L
-1 vs 0.89 µg L-1 in normal controls), 
and LTB4 (1.39 µg L
-1 vs 0.76 µg L-1 in normal controls). The results suggest the potential 
of the target eicosanoids on asthma diagnosis, however, a larger and more extensive study 
will be necessary to confirm the data obtained and to guarantee a greater robustness to 
the approach. 
 
Keywords: Asthma; Biomarkers; Eicosanoids; MEPS; UHPLC. 
 
 
1 Introduction 
Asthma is a noncommunicable chronic disease usually characterized by chronic airway 
inflammation, bronchial hyperresponsiveness and recurrent episodes of reversible airway 
obstruction [1]. It affects about 300 millions people all over the world [2] with a special 
prevalence in children from high income countries [3]. This disease is particularly 
problematic given that it consists of many different phenotypes, each with its own 
etiologic and pathophysiologic factors, being considered a multifactorial syndrome with 
a challenging diagnosis [4]. 
In order to improve asthma diagnosis and treatment, considerable efforts have been made 
to study potential biomarkers able to discriminate different phenotypes of this disease [5]. 
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Currently, several asthma biomarkers have been found in different biological fluids. In 
airway remodeling, elevated levels of Th2 cytokines and eosinophilia were observed in 
the bronchoalveolar lavage (BAL) and endobronchial biopsies of asthmatic patients. The 
presence of different types of granulocytes, (neutrophils, eosinophilsa and exosomes), 
and signaling proteins obtained in the induced sputum of asthmatics, helps to identify the 
phenotype. Also, the fraction of exhaled nitric oxide (FeNO) has been measured routinely 
by means of commercially available analyzers [6]. Even though bronchial biopsies, BAL 
and induced sputum are highly relevant to assess the airway physiology and integrity, 
they are particularly invasive to obtain and generally require trained personnel to make 
the collection, being relatively inaccessible to obtain. Blood is less invasive to obtain and 
contains endogenous analytes that provide a good overview of the metabolic status of the 
patient and potentially of its airway inflammation (e.g. eosinophilia, chemokines and 
cytokines) but still requires trained personnel to collect with some degree of evasiveness 
[6-8]. 
Therefore, there is a need of biosamples that can be easily collected, through non-invasive 
sampling strategies. Totally non-invasive sampling procedures, such as urine collection, 
are especially appealing for the child population . It is easily obtained across the full age 
spectrum, and possesses an array of molecular biomarkers related to airway inflammation 
[9], including the arachidonic acid end products [10]. Enzymatic peroxidation of the 
arachidonic acid is a fundamental process that leads to the formation of bioactive 
eicosanoids such as prostaglandins and leukotrienes, key mediators of airway 
inflammation and response modulation in airways [11] with a strong potential as asthma 
biomarkers, in assessing its progression and follow of the therapy efficiency [5, 9]. 
To date, several analytical platforms have been developed in order to study urinary levels 
of eicosanoids in asthmatic patients including the traditional sample preparation 
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techniques such as liquid-liquid extraction (LLE) [12] and SPE [12, 13], usually 
hyphenated to mass spectrometry; and enzyme immunoassays [14, 15], an alternative to 
chromatography. Even though these techniques are widely used among researchers, they 
are not easily hyphenated to an analytical platform, expensive, time consuming, 
unfeasible sampling procedure, need considerable amounts of harmful organic solvents 
with strong environmental implications, especially in the case of LLE, and requires 
substantial amounts of sample [16]. 
Microextraction techniques emerged in the 90’s with SPME [16, 17] and up to date, a 
noteworthy number of different microextraction techniques are continuously being 
developed including needle-based sampling techniques such as MEPS [18], a 
miniaturized SPE technique consisting of a removable cartridge containing a sorbent, and 
a syringe-like sampler device, which can be manual, semi-automatic or fully automatic 
[19]. This technique has been recently applied in the analysis of urine samples for the 
characterization of, among other, environmental/occupational derived metabolites [20, 
21], psychoactive metabolites [22, 23] and disease potential biomarkers related to asthma 
[24]. The miniaturization of the sample treatment techniques and their improvement in 
terms of sensitivity has allowed the use of absorbance detection techniques [19], 
hyphenated to liquid chromatography, such as photodiode array (PDA) and UV at a 
relative reduce cost compared to mass spectrometry. 
Taking into consideration the most recent trends in liquid chromatography, UHPLC has 
been widely spread due to its increased sensitivity, resolution and time of analysis. 
Therefore, the present work aimed to develop a highly sensitive MEPS/UHPLC-based 
approach, to identify and quantify lipid peroxidation biomarkers related with asthma – 
LTE4, LTB4 and 11βPGF2α – present in urine of asthmatic patients and healthy 
individuals. The most extraction efficiency-influencing experimental parameters, 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 6 
 
including the sorbent material, the number and mode (extract-discard and extract-eject) 
of sample and eluent loading cycles, the pH, the volume of elution solvent and the 
conditioning solvent, were evaluated and optimized by means of a univariate 
experimental design. In addition, important instrumental parameters with influence on the 
chromatographic resolution, such as composition of the mobile phase, the nature of the 
stationary phase of capillary column and the flow rate of mobile phase, were also 
optimized. The stability of eicosanoids extracts was checked over a period of 24 hours 
with sampling throughout a single day. The proposed methodology was applied to the 
analysis of children urine with allergic asthma and healthy children, used as control group. 
 
2 Materials and methods 
2.1 Reagents and materials 
All standards and reagents were of analytical grade with a purity higher than 98%. 
acetonitrile (ACN; 99.9%) and methanol (MeOH; 99.9%) were obtained from Fisher 
Scientific (Leics, UK). Formic acid (FA; 98%), ethanol (EtOH; 99.5%), calcium chloride-
2-hydrate, sodium sulphate anhydrous, sodium carbonate anhydrous, potassium di-
hydrogen phosphate and sodium hydroxide (NaOH) were acquired from Panreac 
(Barcelona, Spain). Magnesium chloride-6-hydrate and potassium chloride were 
purchased from Honeywell Riedel-de-Haën AG (Seelze, Germany). Tri-Sodium citrate-
2-hydrate and ammonium chloride were acquired from Merck (Darmstadt, Germany) and 
sodium chloride from Sigma-Aldrich (Buchs, Switzerland). Ultrapure water (18 MΩ cm 
at 23 °C) was prepared using a Milli-Q water purification system (Millipore, Milford, 
MA, USA). Kaempferol, used as internal standard (IS), was acquired from Fluka 
Biochemica AG (Buchs, Switzerland). LTB4, LTE4 and 11PGF2α standards were 
acquired from Cayman Chemical Co. (MI, USA). 
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The eVol® XR hand-held automated analytical syringe (500 μl) and the BINs: C18, C8, 
C2, SIL, M1, HLB-DVB, R-AX and R-CX, containing the sorbent used in 
microextraction procedure were purchased from SGE Analytical Science Europe, Ltd. 
(Milton Keynes, United Kingdom). The polymeric sorbents PEP, VAX and PGC were 
from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). 
The capillary columns and pre-columns: Acquity UPLC® BEH C18 (2.1 × 50 mm) 
protected with an Acquity UPLC® BEH C18 VanGuard™ Pre-column (2.1 × 5 mm), 
Acquity UPLC® HSS T3 (2.1 × 100 mm) protected with an Acquity UPLC® HSS T3 
VanGuard™ Pre-column (2.1 × 5 mm), Acquity UPLC® CSH C18 (2.1 × 150 mm) 
protected with an Acquity UPLC® CSH C18 VanGuard™ Pre-column (2.1 × 5 mm) and 
CORTECS UPLC® C18 (2.1 × 100 mm) protected with a CORTECS UPLC® C18 
VanGuard™ Pre-column (2.1 × 5 mm), were acquired from Waters Portugal (Lisboa, 
Portugal). The Kinetex® HILIC (2.1 × 100 mm) protected with SecurityGuard™ ULTRA 
cartridge for HILIC UHPLC (2.1 × 2 mm) was supplied by Tecnocroma – Técnicas 
analíticas, LDA (Caldas da Rainha, Portugal). 
 
2.2 Standard solutions and synthetic urine  
Individual stock solutions of all standards were prepared in EtOH at 10 mg L-1 for the 
LTB4 and LTE4, and 1 g L
-1 for the 11βPGF2α and the IS. Stock solutions of the LTB4 
and LTE4 were used as working solutions, whereas for 11βPGF2α and IS the working 
solutions were diluted in EtOH at concentrations of 100 mg L-1 and 1 mg L-1, respectively. 
All stocks and working solutions were aliquoted in 2 mL amber glass vials and stored at 
-80 ℃. 
A synthetic urine (SU) solution was prepared according to Wilsenach et al. [25] with 
slight modifications (Table 1SM, Supplementary Material). Prior to its use, the pH of 
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synthetic urine was adjusted to 5.1 (Mettler Toledo™ EL20 Benchtop pH Meter for 
Teaching and Learning, Mettler Toledo AG, Switzerland) with 10% FA and 1M NaOH, 
and filtered through a 0.2 µm membrane PTFE filter (Merck Millipore, Milford, MA, 
USA). The pH of real urine samples including an unspiked real urine (USRU), were 
adjusted to 5.1, centrifuged at 5000 rpm (2739 × g; Sigma 3K30, Sigma Laborzentrifugen 
GmbH, Germany) for 15 minutes at 5 ℃, and the supernatants filtered through 0.22 µm 
PTFE syringe filters (BGB Analytik, VA, USA). 
For method development, optimization and validation, the assays were carried out using 
fortified SU with LTB4, LTE4 and 11βPGF2α at different concentrations according to the 
sensitivity of the UHPLC-PDA and the amount of eicosanoids present in urine. 
The stability of the extracts was evaluated in extracts of spiked SU at low level (LL; 25 
µg L-1 for the 11βPGF2α, and 2.5 µg L-1 for the LTB4 and LTE4) and medium level (ML; 
100 µg L-1 for the 11βPGF2α, and 10 µg L-1 for the LTB4 and LTE4) of concentrations. A 
set of 4 replicates were taken and analyzed at 0, 8, 16 and 24 hours after extraction. This 
parameter, evaluated by comparing the concentration at each time compared to the 
concentration at time 0, was calculated as follows:  
Stability (%) = (Ati/At0) × 100 
where Ati represents the analyte concentration measured at the specific time and At0 
represents analyte concentration measured immediately after MEPS procedure (0 hour), 
time point zero. This parameter allowed us to know how long the eluates can be in the 
sample manager chamber before analysis without compromising the integrity of the target 
analytes. 
 
2.3 Sample collection and preparation 
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Asthmatic children (N = 27, age = 8.8 ± 4.6Y) were recruited from the emergency and 
allergology service at Hospital Dr. Nélio Mendonça (Funchal Hospital) and diagnosed 
with uncontrolled asthma symptoms, while urine samples from healthy children (N = 17, 
age = 7.8 ± 1.4Y) were collected at two schools in Funchal, Portugal: EB1/PE Tanque – 
Monte and EB1/PE Visconde Cagongo. Relevant information for the study including 
gender, age and other information such as familiar diseases, home characteristics, type of 
disease including clinical data (controlled or not controlled disease, and clinical 
symptoms), therapies, among others, were obtained at sample collection (Table1). 
< Table 1 near here > 
The study was performed in accordance with the principles contained in the Declaration 
of Helsinki and approved by the Ethical Committee for Health of Funchal Hospital 
(SESARAM, EPE) and by Regional Direction of Education (DRE). All tutors of the 
individuals signed an informed consent to participate in the study after being informed 
about the purpose of the study. 
No restrictions were applied to the individuals. Each individual, healthy or asthmatic 
patient, provided a urine sample in a 100-mL urine beaker with integrated transfer device 
(Greiner Bio-One GmbH, Austria), transported to the laboratory in a portable cooling 
box, suitable for this kind of biological samples, where were aliquoted in 8-mL glass vials 
(in order to avoid freezing and thawing cycles) and immediately frozen at -80 ℃ in order 
to quench any rapid degradation activity such as oxidation of labile metabolites as well 
as various enzymatic reactions. Compared with other biofluids, urine offers several 
advantages since it is obtained through an easy and totally non-invasive sampling 
procedure, may be collected across all ages even in severe patients, is a rich source of 
metabolites and its composition reflects the imbalances of all biochemical pathways 
within the body. 
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2.4 Isolation of targeted analytes by MEPS 
The targeted analytes, LTB4, LTE4 and 11PGF2α, were isolated from urine using a semi-
automatic miniaturization of solid phase extraction, the MEPS. This off-line procedure 
combines a digitally controlled and programmable semi-automatic device (eVol® XR) 
that controls the aspiration/dispensing volume and flow rate with minimal user 
interference allowing greater precision and accuracy and consequently greater 
reproducibility; a gas-tight XCHANGE® analytical syringe (500 µL); and a removable 
MEPS cartridge, known as ‘barrel insert and needle’ (BIN), containing 1-4 mg of a solid 
packed sorbent bed. This experimental procedure includes: (i) an activation process of 
the sorbent with water and methanol, (ii) the conditioning of the sorbent usually 
performed with the elution solvent, (iii) the sample loading where the sample is forced to 
pass through the sorbent bed several times, in order to efficiently retain the analytes of 
interest, (iv) a washing step to remove unwanted analytes not retained in the sorbent; and 
finally (v) the elution where the analytes were eluted using an appropriate solvent [19]. A 
SU sample spiked at 40 µg L-1 for the LTB4 and LTE4, and 160 µg L
-1 for the 11PGF2α, 
was used in the optimization of the experimental parameters with influence on the MEPS 
efficiency. The chemical nature of the sorbent material, the number and mode (extract-
discard and extract-eject) of sample loading cycles, the pH, the volume of elution solvent 
and the conditioning solvent, were evaluated and optimized by means of a univariate 
experimental design. 
The extraction efficiency of 11 commercially available MEPS sorbents including, C18 
(octadecyl-silica), C8 (octyl-silica), C2 (ethyl-silica), SIL (silica), M1 (80% C8 + 20% 
SCX – strong cation exchange), PEP (polar enhanced polymer), VAX (verify AX; C8 + 
SAX – strong anion exchange), HLB-DVB (hydrophilic-lipophilic-balanced reversed-
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phase sorbent, divinylbenzene), PGC (porous graphitic carbon), R-AX (retain anion 
exchange) and R-CX (retain cation exchange), was evaluated and optimized in order to 
select the sorbent that offers the best performance for isolation of targeted eicosanoids. 
The main characteristics of the MEPS sorbents used in this study are represented in Table 
2SM. 
The number of loading cycles was optimized by drawing up 250 µL of sample, 3, 5 and 
10 times, while the mode of the loading cycle was evaluated by drawing up the sample 
and ejecting in the same vial (extract-eject) and by drawing up the sample and discarding 
as waste (extract-discard). 
The influence of pH was evaluated by testing the extraction efficiency at three different 
pH values (2.8, 5.1 and 8.5), adjusted with NaOH at 1M or FA at 10%, in two opposite 
ion exchange MEPS sorbents: R-AX and R-CX. 
In order to investigate the best elution conditions, the impact of different elution solvents 
was investigated with different solvent solutions based on pure ACN, pure MeOH, 
acidified ACN and acidified MeOH, and different proportions of ACN and MeOH (50:50, 
75:25 and 25:75). An aqueous solution of FA at 0.1% was also used to investigate if any 
of our target analytes were washed away in the washing step. After solvent selection, the 
elution volume (50 µL and 100 µL) and the number of cycles (1, 2 and 3 times) was also 
investigated. 
Eluates were eluted directly into 100-µL micro-inserts (VWR International - Material de 
Laboratório, Lda., Carnaxide, Portugal), proper for 2-ml vials. In addition, the total 
dryness of the eluate and its resuspension in 50 µL and 100 µL of mobile phase (95% 
water at 0.1% FA and 5% ACN at 0.1% FA) and the concentration of the eluate until half 
of its volume (without dryness) were also investigated. 
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An important step in MEPS is the conditioning of the sorbent since it can influence the 
performance of the extraction. It consists on the clean up to avoid carry-over, and 
regeneration of the active sites in the sorbent for its reuse. According to Pereira et al. [26], 
different organic solvents can be used to perform this step. In this regard, the effect of the 
conditioning solvent was performed by testing two common organic solvents, 250 µL of 
ACN and 250 µL of MeOH, followed by an equilibration with 250 µL of FA at 0.1%. 
The number of conditioning-equilibration cycles (1, 2 and 3 times) were tested in order 
to suppress the carry-over effect. 
In all steps of the MEPS procedure the aspiration and dispensing flow rate was limited to 
minimum (20 µL s-1) in order to increase the interaction time of the analytes with the 
sorbent and to minimize the occurrence of cavitation. All extractions were made in 
duplicate (N = 2). 
 
2.5 Chromatographic conditions. Optimization 
The analysis of the target analytes was carried out on a Waters Ultra Performance Liquid 
Chromatographic Acquity system (UPLC Acquity H-Class, Waters Corporation, Milford, 
MA, USA) equipped with a 2996 PDA detector, a Waters Acquity quaternary solvent 
manager (QSM), an Acquity sample manager, a column heater and a degassing system. 
The whole configuration was driven by Empower software v2.0 (Waters Corporation). In 
order to achieve the best performance, important instrumental parameters with influence 
on the chromatographic resolution: composition of mobile phase, and nature of the 
stationary phase of capillary column, were optimized. Several types of columns with 
different dimensions including Acquity UPLC® BEH C18 protected with an Acquity 
UPLC® BEH C18 VanGuard™ Pre-column, Acquity UPLC® HSS T3 protected with an 
Acquity UPLC® HSS T3 VanGuard™ Pre-column, Acquity UPLC® CSH C18 protected 
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with an Acquity UPLC® CSH C18 VanGuard™ Pre-column, CORTECS UPLC® C18 
protected with a CORTECS UPLC® C18 VanGuard™ Pre-column, and Kinetex® HILIC 
protected with SecurityGuard™ ULTRA cartridge for HILIC UHPLC, were  evaluated 
in terms of peak resolution, shape and measurable areas of the target analytes (Table 2).  
These parameters were developed with spiked SU and real urine at the same concentration 
as described in a previous section. The optimized gradient was as follow: (A) water at 
0.1% FA and (B) ACN at 0.1% FA, filtered through a 0.2 µm PTFE membrane: 95% A 
(0 min), 47% A (9.5 min), 24% A (11 min), 0% A (11.1 – 12.1 min) and 95% A (14 min) 
followed by a re-equilibration time of 2 minutes. The vials containing the extracts were 
kept inside the sample manager at a temperature of 15 ℃. The flow rate was 300 µL min-
1, the injection volume was set at 5 µL and the capillary columns thermostatted at 30 ℃. 
For quantification purposes, the detector was set to 4 distinct channels corresponding to 
the maximum absorbance wavelength of each target analyte and IS (see Table 3). The 
identification of the target analytes was made by comparison of the retention time and 
UV-Vis spectral characteristics with those of pure standards and confirmed by the 
standard addition to the eluates. All UPLC injections were carried out in triplicate (N = 
3). 
 
2.6 Method validation 
MEPS/UHPLC-PDA method was validated according to the International Union of Pure 
and Applied Chemistry (IUPAC) guidelines [27], being assessed the following 
parameters: selectivity, linearity, method limits, precision, accuracy, extraction efficiency 
and matrix effect. 
The method selectivity was assessed by analyzing the absence of interfering components 
at the retention time of the eicosanoids. 
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Linearity was evaluated by spiking SU at different concentrations. A seven-point 
calibration curve for LTE4 and 11βPGF2α, and nine concentration levels for the LTB4 
were constructed from the least square linear regression model with a weighing factor of 
1/×2 by plotting the peak area ratio between each eicosanoid and the IS (Areaanalyte/AreaIS) 
against the eicosanoid concentration. Since the evaluation of the coefficient of 
determination (r2) as a measure of linearity may be misleading, the proportional ratio 
using chromatographic signal and eicosanoid concentration was confirmed by means of 
the F-test through the lack-of-fit, goodness-of-fit and Mandel’s fitting tests. 
The method limits were expressed in terms of LOD, defined as the lowest concentration 
of analyte which can be reliably detectable and identified with an acceptable precision 
and accuracy (commonly within 20% RSD and within 20% bias), and LOQ, defined as 
the lowest concentration of analyte which can be identified and quantified with a 
satisfactory precision and trueness [28]. These parameters were calculated from the least 
squares linear regression analysis being LOD defined as: a + 3.3Sa/b and LOQ as: a + 
10Sa/b, where a represents the origin ordinate, Sa represents the standard deviation of the 
experimental value closest to the intercept, and b the slope of the calibration curve. 
The matrix effect was calculated by the ratio between the slope of the standards in USRU, 
obtained in the least squares linear regression analysis, and the slope of the standards in 
SU:  
Matrix effect (%) = (slopeUSRU/slopeSU)×100 
 where slopeUSRU and slopeSU are the slope obtained from the analytical curve of the 
USRU and SU respectively. 
In order to determine precision, accuracy and recovery percentage, the SU was spiked at 
three concentration levels corresponding to the LL (25 µg L-1 for the 11βPGF2α, and 2.5 
µg L-1 for the LTB4 and LTE4), ML (100 µg L
-1 for the 11βPGF2α, and 10 µg L-1 for the 
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LTB4 and LTE4) and high level (HL; 200 µg L
-1 for the 11βPGF2α, and 20 µg L-1 for the 
LTB4 and LTE4), covering the entire calibration range. Precision (expressed as percentage 
of relative standard deviation, % RSD) was evaluated in terms of intraday repeatability 
obtained from the analyzes of 4 replicates of spiked SU performed at the same day, and 
analyzed in the same analytical run, assayed in three different runs (N = 12) over a period 
of three days (reproducibility; N = 27). 
Accuracy refers to how close the concentration values obtained experimentally are to the 
nominal values and is calculated as follow:  
Accuracy (%) = (xi/x) × 100 
where xi represents the experimental concentration values and x the nominal 
concentration values of the analyte. This parameter was calculated with the data obtained 
in the least squares linear regression analysis. 
The recovery study allowed the evaluation of the extraction efficiency carried out in 
duplicate (N = 2) for each level of concentration. Briefly, one set of aliquots of SU was 
spiked with the analytes before the MEPS procedure and another set of unspiked SU went 
through the process and the respective eluates were spiked with the different 
concentration levels of the target analytes. This parameter is calculated by means of the 
following formula:  
Recovery (%) = (SSU/SEluate) × 100 
where SSU represents the obtained concentration of the analytes in the spiked SU when 
added before the MEPS procedure, and SEluate represents the concentration obtained from 
the analysis of the spiked eluates. 
 
2.7 Statistical analysis 
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Further statistical data analysis was performed by means of the IBM SPSS Statistics 
Version 22 (IBM Corp., Armonk, NY, USA). The independent samples t-test is used in 
situations with two experimental conditions with different participants in each condition 
[29]. Regarding this, the t-test was performed on the target analytes values obtained from 
the samples in order to characterize the significant differences among both groups under 
study: the asthmatic patients and normal controls, in terms of mean values. 
 
3 Results and discussion 
With this work, it was intended to develop an easy and quick analytical method able to 
detect and quantify simultaneously three eicosanoids present in urine that are key 
biomarkers of the inflammatory process and asthma metabolomics per se.  
 
3.1 MEPS optimization 
A SU sample spiked at 40 μg L-1 for the LTB4 and LTE4, and 160 μg L-1 253 for the 
11PGF2α, was used in the optimization of the extraction parameters. Each sorbent was 
activated with 1 time 250 µL of ACN and 0.1% FA. 3 loading cycles were used by 
drawing up 250 µL of sample (pH = 5.1) and discarding as waste. 100 µL of 0.1% FA to 
wash the sorbent and the elution of the sample was made with 100 µL of acidified ACN 
(0.1% FA). 
The efficiency of eleven commercial sorbents suitable for eVol®-MEPS format (Fig. 1A) 
was evaluated. Each sorbent has specific chemical properties that make them suitable for 
the extraction of a particular class of compounds (Table 2SM). 
As shown in Fig. 1A, R-AX was the most favorable for the isolation of all targeted 
eicosanoids and thus, was selected as the extraction sorbent for the following 
experiments. Although R-CX and VAX sorbents, show best efficiency for LTB4, the 
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difference is not significant when compared to the overall of the R-AX that had a better 
extraction efficiency for the LTB4. Furthermore, the target analytes, 11PGF2α, LTE4 and 
LTB4, have an acidic nature due to the presence of a carboxylic group making them 
suitable to be extracted by the R-AX. This sorbent is chemically functionalized with 
quaternary amine groups that gives to it a balanced retention capacity between acidic and 
non-polar compounds [19]. 
< Fig. 1 near here > 
The number of loading cycles is determinant when developing a MEPS procedure. This 
parameter was optimized by drawing up 250 µL of sample 3, 5 and 10 times (Fig. 1B). 
The results showed good extraction efficiencies for the LTs, in addition to detection of 
the 11PGF2α when the sample is drawn up and down 10 times through the sorbent. It has 
not been tested more cycles because of sorbent saturation that was reflected on cavitation 
which started to become more prominent with the increase of loading cycles from 5 
cycles. Consequently, more time was needed for each loading cycle and thus a reduction 
on the sorbent lifetime was expected. Additionally, the mode of the loading cycles was 
also tested. The extract-discard mode consists on the drawn up of the sample from an 
aliquot and the waste is discarded, the extract-eject mode involves the drawn-up of the 
sample from an aliquot and the waste is not discarded, returning to the aliquot. The 
extract-discard mode was selected because the obtained performance was slightly better 
(Fig. 1C) for all target analytes. 
The quaternary amine groups present on the surface of the R-AX are strong bases with a 
great acid dissociation constant (pKa > 14), positively-charged at all pHs that, as the name 
indicates, exchange or attracts anionic compounds in solution. R-CX is another ion 
exchange sorbent, functionalized with sulfonic acid groups that have very low pKa (< 1), 
which make it negatively-charged at all pHs [30]. The targeted eicosanoids have low 
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strongest acidic pKa (11PGF2α = 4.36, LTE4 = 2.39 and LTB4 = 4.65 [31]. For this 
reason, at a pH higher than their pKas, most of the analytes would be deprotonated, being 
able to be adsorbed through the surface of a basic sorbent. Although R-CX had the best 
results toward 11PGF2α and in terms of total area, the extraction of LTE4 was not so 
efficient. Hence, R-AX at pH = 5.1 was chosen as the best pH for subsequent experiments 
(Fig. 1D). 
Other important steps in MEPS procedure are washing and elution. The washing step 
allows us to remove undesired matrix interferences that are weakly retained on the sorbent 
while the elution step consists on the use of the best solvent and the least volume possible 
that is able to elute the target analytes retained on the surface of the sorbent [19, 32]. In 
this study, the best elution solvent was MeOH followed by ACN (Fig. 2A). The elution 
volume was also considered and no substantial differences were found between eluting 2 
or 3 times with 50 µL of MeOH (Fig. 2B), therefore, in subsequent experiments, the 
elution was carried out using 2×50 µL of MeOH. The washing solvent, 0.1% FA, was 
also investigated and none of the target analytes were eluted with this solvent making it 
suitable for this step (Fig. 2A). 
The influence of the eluate concentration was investigated. Comparing the obtained areas 
from 50% evaporation of the eluates (until 50 µL) with the areas obtained from complete 
dryness and resuspension in mobile phase (50 and 100 µL), it can be understood that 
complete dryness of the eluates is not appropriate for the target analytes once there are 
losses when resuspended. Evaporation of the eluates until half of its volume was the best 
option not only in terms of areas but also in terms of peak resolution and analyte detection, 
and therefore were used for further experiments. 
< Fig. 2 near here > 
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An important and final/beginning step of the MEPS procedure is the 
conditioning/regeneration of the sorbent. Each MEPS procedure starts with the 
conditioning of the sorbent with an organic solvent followed by its equilibration before 
the loading of the sample and ends with the regeneration of the sorbent that match with 
conditioning step if further extractions are made [26]. The influence of the conditioning 
solvent on the performance of the extractions made with the R-AX sorbent, was assayed 
with two organic solvents: (i) 250 µL of ACN and (ii) 250 µL of MeOH. Each 
conditioning solvent was followed by the previous optimized parameters: equilibration 
with 0.1% FA, 10 sample (pH = 5.1) loading cycles discarded as waste, 100 µL of 0.1% 
FA as washing solvent and elution with 2 × 50 µL of MeOH. The eluates obtained with 
each conditioning solvent were analyzed and the obtained data can be seen on Fig. 2C. 
Even though the best elution solvent was MeOH, it was remarkable to find out that ACN 
is a better surfactant, allowing a greater conditioning of the sorbent. ACN is less viscous 
than MeOH (0.37 centipoise, cp versus 0.55 cp at 20 ℃ (Physical Properties of Solvents 
– https://www.sigmaaldrich.com on November 2017) which can be a determinant factor 
that allows it to be more efficient involving the sorbent micro-particles reaching all spaces 
between them and consequently increasing the number of functionalized groups that are 
conditioned, improving the number of analytes bound to the surface of the sorbent. To 
the best of our knowledge, no previous report was made regarding the optimization of the 
conditioning/regeneration step with different solvents. To avoid carry-over, the number 
of conditioning-equilibration cycles were optimized. The best results, which are the 
smaller number of cycles enough to remove the carry-over, was 3×250 µL of ACN - 250 
µL of 0.1% FA. 
 
3.2 Optimization of chromatographic conditions  
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The gradient of the mobile phase, the flow rate and several types of columns with different 
dimensions and particle sizes were tested and optimized. 
The influence of five commercial columns suitable for UPLC® analysis of eicosanoids 
were evaluated (Fig. 1A-SM and Fig. 2-SM). Each column has specific chemical and 
physical properties that makes them suitable for the separation of a wide range of 
compounds at diverse conditions (Table 2). 
< Table 2 near here > 
The BEH C18 column was selected for its narrow and sharp peaks, reproducible retention 
times and good chromatographic resolution of the target analytes (Fig. 1A-SM) and by 
the areas obtained (Fig. 3A). This column was previously used by Perestrelo et al. [24] 
and Chappell et al. [33] for the analysis of leukotrienes in urine and sputum samples. 
< Fig. 3 near here > 
In terms of gradient and flow rate, the initial conditions selected for the optimization of 
the chromatographic conditions (also used for the optimization of the MEPS procedure) 
were a modification of Perestrelo el al. [24] and were tested with spiked SU. It consisted 
of a BEH C18 column and by a gradient profile composed by (A) water at 0.1% FA and 
(B) ACN at 0.1% FA, at a flow rate of 500 µL min-1: 95% A (0 min), 47% A (9.5 min), 
24% A (11 min), 0% A (11.1 – 12.1 min) and 95% A (14 min) followed by a re-
equilibration time of 2 minutes. The chromatogram obtained is shown in Fig. 1A-SM. 
The best gradient with spiked SU was obtained with a flow rate of 300 µL min-1 as 
follows: 95% A (0 min), 85% A (2 min), 60% A (2.5 min), 45% A (5 min); 95% A (6 – 
7 min) (Fig. 1B-SM) followed by a re-equilibration time of 2 min. 
The best conditions obtained with SU were tested using spiked real urine. As shown in 
Fig. 1C-SM, these conditions were not effective once the analytes were co-eluted with 
urine interferents. A modification of the initial conditions in terms of flow rate (300 µL 
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min-1) were successfully tested with spiked real urine (Fig. 1D-SM) and spiked SU (Fig. 
4). With this optimization, even though we were not able to reduce the run time of 
analysis, a considerable decrease of 40% on the amount of solvent was achieved which is 
important regarding environmental issues and cost of analysis. Regarding the gradient of 
the mobile phase and the flow rate, they were optimized for the best results within a total 
run time of 16 min, including column equilibration. A representative chromatogram 
obtained with the final optimized conditions in SU is shown in Fig. 4. 
< Fig. 4 near here > 
Considering the obtained data, the best chromatographic conditions were obtained using 
a gradient elution mode, with a flow rate of 300 µL min-1, as follows: 95% A (0 min), 
47% A (9.5 min), 24% A (11 min), 0% A (11.1 – 12.1 min) and 95% A (14 min) followed 
by a re-equilibration time of 2 min using an UHPLC-PDA equipped with a BEH C18 
capillary column. 
 
3.3 Method validation 
In order to demonstrate the practicability of the developed analytical strategy and its 
ability to quantify the target analytes in urine samples, the method was fully validated in 
terms of selectivity, linearity, method limits, precision, accuracy, extraction efficiency 
and matrix effect for each eicosanoid. The analytical method figures of merit are 
described in Table 3 and Table 4. 
< Table 3 and Table 4 near here > 
Selectivity was demonstrated by the absence of interfering peaks at the retention times of 
the target analytes in blank SU. Figure 4 clearly demonstrates the absence of interfering 
peaks at the retention times of the target analytes, demonstrating the ability of the 
analytical method to unequivocally identify and quantify the analytes of interest. 
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The linearity was assayed using different calibration curves of each analyte obtained by 
least squares linear regression analysis as described in section 2.6 Method validation. All 
of three regression equations of the target analytes showed a coefficient of determination 
higher than 0.9980 but these values alone, do not guarantee the linearity of the signal. 
Therefore, linearity was assessed by means of the F-test at different approaches: lack-of-
fit test, based on the analysis of the residual variance; goodness-of-fit test, based on the 
ratio between the mean sum of squares of the factors and the residuals; and Mandel’s 
fitting test, based on the difference between the residual standard deviation of the obtained 
first-order calibration model and a potential second-order calibration model,  as described 
by Kruve et al. [34]. The signal is considered linear when the calculated F, by means of 
the experimental data, is lower than the respective tabulated F. As show in Table 3, all 
signal linearities calculated (Lack-of-fit, Godness-of-fit and Mandel’s tests) by the 
previous mentioned approaches, are confirmed (Fcalculated < Ftabulated) with a 95% 
confidence level. 
The method limits can be described as the lowest value of concentration at which the 
method is able to detect (LOD) and quantify (LOQ) the target analytes (Table 3) with 
satisfactory accuracy and precision. As previously reported, the developed method 
showed low values of LOD which ranged between 0.04 µg L-1 for LTB4 and 1.12 µg L
-1 
for 11PGF2α while LOQ values ranged between 0.10 µg L-1 for the LTB4 and 2.11 µg 
L-1 for 11PGF2α. 
Matrix effect was also evaluated in order to determine which calibration curve should be 
used during the real sample analysis. The values obtained with this test is represented in 
Table 3. All the target analytes have revealed considerable matrix effects with 73% for 
the 11PGF2α, 76% for the LTE4 and 81% for the LTB4. Consequently, the regression 
equation obtained with real urine would be used for further real sample analyzes. 
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An important parameter when validating a method is precision. This parameter can be 
defined as repeatability at which the % RSD is calculated in order to assess the error 
associated between replicates performed in the same day, and as reproducibility at which 
the % RSD is calculated in order to assess the error associated between replicates 
performed over a certain period of days. The developed method proved to have 
repeatability with % RSD values that ranged from 3.11% for LTE4 at HL and 6.63% at 
LL for the same analyte. As for reproducibility, % RSD values ranged from 1.29% for 
LTE4 at HL and 10.43% at LL for the same compound being LTE4 on the extremes of 
both precision approaches (Table 4). 
The performance of the method can also be assayed as accuracy. In general, all 
experimental values have shown to be accurate (approximately 100%) during the study 
of this parameter with less than 7% deviation from the tabulated value as shown in Table 
4. The least accurate was 11PGF2α at LL with 93.62% and LTB4 the most accurate with 
100.04%. 
The extraction efficiency was evaluated in order to know how much of the target analytes 
is lost during extractions. The obtained recovery percentage for 11PGF2α ranged 
between 95.52% at a LL and 99.71 at a ML; LTE4 ranged between 74.99% and 91.13% 
at HL and LL respectively; and LTB4 ranged from 84.53% at LL and 92.25% at ML 
(Table 4). 
The analytical performance of MEPS/UHPLC-PDA analysis for the quantification of 
urinary eicosanoids was compared with several other methodologies reported in the 
literature in the last years for the same group of compounds using other extraction 
procedures, as described in Table 5. Our developed technique involves lower elution 
volumes, sample amounts and it is much faster (time of extraction falling few minutes), 
than the described. In addition, the MEPS procedure was carried out in a semi-automatic 
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way which is a guarantee of a high precision. Regarding the analytical performance, 
MEPS/UHPLC-PDA allows equal or even better LODs and LOQs than other published 
studies with excellent recoveries and extraction efficiency. 
< Table 5 near here > 
 
3.4 Stability of the extracts 
The stability of the extracts was tested with target analytes at different concentrations (LL 
and ML), over a 24-hour period with analyzes running each 8 hours. 
It was found out that eluates were stable for 8 hours, with less than 6% lost during the 
tested time, but after that time, the leukotrienes stability decrease, being the 11PGF2α 
the most stable with less than 7% lost during the assay as observed in Fig. 3B. All the 
analysis were performed taking into account the stability of the extracts. 
 
3.5 Application of the developed methodology to real samples 
3.5.1 Individuals characterization 
The main characteristics of the subjects of this study are shown in Table 1 (see Section 
2.3).  
Family history is strongly related to asthma. Most of the asthmatic patients (81.0%) that 
took part of this study, had a family member with asthma being the majority (66.7%), 
maternal-related. This trend has been reported by Valerio et al. [39] where children with 
relatives with asthma are 2 to 4 times more likely to have an asthma diagnosis than 
children with no asthmatic relatives. Even though family history is strongly related to the 
asthmatic diagnosis in children, many of our asthmatic patients did not have any relative 
with asthma (19%) and many of the normal controls (59%) had a relative with an 
asthmatic diagnosis during their lifetime but no asthma or any allergen sensitization was 
reported by this group. In the present work, it was interesting to find that most of the 
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asthmatic patients were boys (59% of total population of asthmatic patients and 74% of 
asthmatic patients until 13 years old) being in accordance with the pattern of other 
countries [40]. Although the prevalence of asthma is higher in boys at this age (< 13 years 
old), the risk of developing asthma increases rapidly in women after puberty [41]. It is 
believed that these changes might have a relationship to the endocrine system, specifically 
to leptin, an hormone produced by adipocytes, related to inflammation [42] and asthma 
in children [43]. 
The main comorbidity found throughout this study was allergic rhinitis with 93% of the 
asthmatic patients with allergic asthma having also rhinitis. Although higher, this value 
is in agreement with the literature [44] which stated that allergic rhinitis coexists in 60 to 
80% of allergic asthmatic children probably because of their similar pathophysiology. 
This comorbidity has also been found not only in children but also in general asthmatic 
population in lower values (52.3%) [45]. The most common allergen sensitization, among 
the allergic population under study, was sensitivity to house dust mites (70% of the 
allergic population) followed by animal epithelium and pollens, with 56% and 37% 
respectively. A similar trend was previously reported by Boulet et al. [46]. 
 
3.5.2 Quantification of urinary eicosanoids in asthmatic patients and healthy individuals 
In order to evaluate the applicability of the method to urine samples, R-AX sorbent and 
the developed method proposed in this study were applied to detect the three eicosanoids 
– 11PGF2α, LTE4 and LTB4, in urine of 27 asthmatic and 17 healthy children. The 
concentration values obtained for the urine of each asthmatic patient and healthy 
individual (control) is represented in Table 3SM. Fig. 5 represents a chromatogram of an 
asthmatic patient and another from a normal control. Even though these eicosanoids are 
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at very low concentration, in a complex matrix, it is clear the difference on peaks intensity 
between controls and asthmatic groups. 
< Fig. 5 near here > 
A third part of the normal controls had values bellow the limit of quantification or 
detection, except for the 11PGF2α that was not detected in 2 asthmatic patients. In both 
groups, the major analyte was 11PGF2α with greater values when compared to the two 
LTs of this study (Fig. 6). 11PGF2α values varied from bellow the LOD (< LOD) until 
310.32 ± 9.59 µg L-1 for the asthmatic patients group, and from 32.16 ± 1.00 until 167.29 
± 17.75 µg L-1 for the normal controls. LTE4 values varied from < LOD until 4.94 ± 0.22 
µg L-1 for the asthmatic group, and from 0.47 ± 0.06 until 2.53 ± 0.41 µg L-1 for the 
normal controls. The tendency for the LTB4 was the same with values between < LOD 
and 2.64 ± 0.05 µg L-1 for asthmatics and < LOD and 1.74 ± 0.05 µg L-1 for normal 
controls. 
< Fig. 6 near here > 
Before running the t-test some specific assumptions required to be evaluated including 
the type of the variables, independence of observations, normal distribution, outliers and 
homogeneity of variances [29]. The results have shown that there are significant 
differences between groups. For this procedure, the logarithmic values of concentrations 
were used in order to obtain closer values to the normal pattern. For the 11PGF2α, the t-
test value was 7.415 with 289.6 degrees of freedom (df; p < 0.001); the LTE4 had a t-test 
value of 3.653 (df = 217, p < 0.001) and LTB4 had 5.437 (df = 198, p < 0.001). The mean 
values calculated by means of the t-test procedure of each target analyte and investigated 
group, are shown in Table 3SM. 
Prostaglandin D2 is a major cyclooxygenase metabolite produced during an inflammatory 
response by mast cells and leukocytes as dendritic cells and type 2 T helper cells with a 
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pro-inflammatory role. This unstable eicosanoid is rapidly transformed into more stable 
products, prostaglandins of the J series and 11PGF2α [47]. As prostaglandin D2, 
11PGF2α also has biological activity as bronchoconstrictor and contraction of coronary 
arteries [48], and can be found in increased values in the urine of asthmatic patients after 
allergen-induced  bronchoconstriction [49] and after exercise challenge [50]. On average, 
the asthmatic patients had higher concentrations of 11PGF2α (112.96 µg L-1) than normal 
controls (62.56 µg L-1) with a mean difference of about 50.40 µg L-1 between groups. 
This significant difference (p < 0.001) represent a medium-sized effect (r = 0.40). The 
difference among the total population was between 35.97 and 64.83 µg L-1 for this 
eicosanoid, with a confidence level of 95%. 
Cysteinyl leukotrienes, powerful bronchoconstrictors, 100 to 1000 times more powerful 
than histamine [51], play an important role in the pathophysiology of asthma. They also 
have a role in the vascular permeability allowing the exudation of inflammatory cells 
from plasma to the airway mucosa, stimulate mucus secretion and inhibit mucociliar 
clearance – characteristics of the pathophysiology of asthma [51]. Since LTC4 and LTD4 
are biologically converted into LTE4, they are not excreted in measurable concentrations 
in urine. Therefore, LTE4 is considered a biomarker of the total of cysteinyl leukotrienes 
levels in urine [52]. Studies suggest that LTE4 is dependent on allergen dose inhaled 
during allergen challenge in asthmatic patients [53]. Having this into account, in the 
evaluation of the groups present in this study, it was found increased mean levels of LTE4 
in the urine of asthmatic patients with 1.27 µg L-1 against 0.89 µg L-1 in normal controls 
with a mean difference of 0.38 µg L-1. This difference was significant (p < 0.001) and 
represented a small-sized effect (r = 0.24). Regarding the total population, the difference 
was of 0.11 – 0.64 µg L-1 with a confidence level of 95%. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 28 
 
LTB4 is produced by a diversity of cells including neutrophils and macrophages and it is 
a powerful pro-inflammatory chemoattractant whose main targets are neutrophils 
promoting their activation, adhesion to the endothelium and chemotaxis. This LT also 
activates neutrophils degranulation of additional mediators and it is also involved in 
inflammatory pain by neutrophils dependent processes [51]. LTB4 tend to be in higher 
concentrations in diverse matrices like exhaled breath condensate [54], sputum [55] and 
urine [24]. The asthmatic patients of our investigations had a tendency for higher values 
of LTB4 with a mean concentration of 1.39 µg L
-1 in the urine of asthmatics patients 
against 0.76 µg L-1 in the normal controls (mean difference = 0.63 µg L-1). This difference 
was significant (p < 0.001) and represented a medium-sized effect (r = 0.36). In terms of 
total population, the difference varied between 0.47 and 0.78 µg L-1 with a confidence 
level of 95%. 
 
4 Conclusions 
Throughout this work, it was developed a powerful methodology to simultaneously detect 
and quantify urinary eicosanoids in asthmatic patients and healthy individuals as powerful 
strategy to identify potential asthma biomarkers. 
The developed MEPS/UHPLC-PDA approach have proven to be an ultra-fast, accurate, 
precise and easy analytical strategy. The extraction procedure in not time-consuming with 
a total analysis time of 31 min. Furthermore, The MEPS/UHPLC-PDA procedure 
revealed to be environmentally friendly due to the reduce levels of harmful organic 
solvents consumed during both extraction and analytical procedures. The validation of 
the method revealed compatible values for each parameter including selectivity, linearity, 
method limits, precision, accuracy, extraction efficiency, matrix effect and extracts 
stability for each eicosanoid. Therefore, it was possible to successfully apply the method 
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to the samples and discriminate between asthmatics and healthy individuals. On average, 
the urine of asthmatic patients presented significantly higher concentrations of all 
eicosanoids. The obtained values for the 11βPGF2α and LTB4 were about 1.8 times higher, 
and for the LTE4 were about 1.4 times higher in asthmatic patients than in healthy 
individuals suggesting the potential of these eicosanoids on asthma diagnosis. 
Consequently, MEPS/UHPLC-PDA reveled to be a promising method regarding the 
study of these and other eicosanoids present in other biological matrices as plasma, 
sputum and EBC of patients from inflammatory illnesses other than asthma. 
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Figure captions 
Fig. 1 (A) Comparison of the efficiency of eleven commercial MEPS sorbents; (B) 
number and (C) mode of loading cycles of the sample; and (D) influence of the pH of the 
sample in two ion exchange sorbents: R-AX and R-CX. Values are expressed as mean ± 
standard deviation (N = 6). 
Fig. 2 (A) Influence of the elution solvent and (B) volume on the extractions; (C) 
conditioning step solvent. Values are expressed as mean ± standard deviation (N = 6). 
Fig. 3 (A) Influence of five commercial columns suitable for UPLC® analyzes. Values 
are expressed as mean ± standard deviation (N = 3). (B) Stability of extracts at 0, 8, 16 
and 24 hours after extraction. Target analytes were at low level (LL; 25 µg L-1 for the 
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11βPGF2α, and 2.5 µg L-1 for the LTB4 and LTE4) and medium level (ML; 100 µg L-1 for 
the 11βPGF2α, and 10 µg L-1 for the LTB4 and LTE4) of concentration. 
Fig. 4 Representative chromatograms of a blank synthetic urine and synthetic urine 
spiked with the investigated standards: (1) 11β-prostaglandin F2α (300 µg L-1), (2) 
leukotriene E4 (30 µg L
-1) and (3) leukotriene B4 (30 µg L
-1) – at the best optimization 
parameters obtained at (A) 192 nm and (B) 281 nm. Chemical structures of the target 
analytes are attached on the side of the respective peak.  
Fig. 5 Representative chromatograms of urine from a normal control (CTRL) and urine 
from an asthmatic patient (ASMT) at (A) 192, (B) 281, and (C) 270 nm. Numbers 
represent the target analytes: (1) 11β-prostaglandin F2α, (2) leukotriene E4 and (3) 
leukotriene B4. Boxes on the up-right corner of each chromatogram represent the 
magnification of the target analyte peak. 
Fig. 6 Average concentrations of 11β-prostaglandin F2α (11βPGF2α), leukotriene E4 
(LTE4) and leukotriene B4 (LTB4) obtained in the urine of asthmatic patients and healthy 
individuals. 
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Table 1 
Characteristics of the asthmatic patients and healthy individuals (control group). 
 Subjects Asthmatic patients Healthy individuals 
n 27 17 
Age (years; mean ± std) 8.8 ± 4.6 7.8 ± 1.4 
Gender (male:female) 16:11 10:07 
Pathology    
Allergic asthma 26 (96%) 0  
Allergic asthma + allergic rhinitis 25 (93%) 0  
Allergic asthma + sinusitis 2 (7%) 0  
Allergic asthma + conjunctivitis 7 (26%) 0  
Allergic asthma + eczema 14 (52%) 0  
Allergens    
House dust mites 19 (70%) 0  
Pollens 10 (37%) 0  
Animal epithelium 15 (56%) 0  
Moulds 3 (11%) 0  
Cockroaches 5 (19%) 0  
Initial diagnose (intermittent:mild:moderate:severe:n/aa) 6:3:12:0:4  - 
Uncontrolled asthma 27 (100%) 0  
Exacerbation in last 12 months 23 (85%) 0  
Missed school in last 12 months because of illnessb 23 (85%) 8 (47%) 
Parent/Tutor missed work in last 12 months because of the childb 14 (52%) 7 (41%) 
Smoker 3 (11%) 0  
Have family members with asthma 22 (81%) 10 (59%) 
Relatives with asthma (only paternal:only maternal) 4:13 0:4 
Both relatives with asthma 5 (19%) 6 (35%) 
Without relatives with asthma 5 (19%) 7 (41%) 
a n/a – no answer. 
b Because of asthma, in the case of the asthmatic patients and because of any illness, in the case of normal 
controls. 
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Table 2 
Properties of the UPLC columns used in this study. 
Chromat
ographic 
mode 
Name Chemistry Particle 
technolog
y 
Particl
e size 
(µm) 
surface 
area 
(m2/g) 
pH 
range 
Pressu
re 
Stabili
ty 
(psi) 
Temperature 
limits (℃) 
Properties and purpose 
Low 
pH 
High pH 
Reversed 
phase 
Acquity 
UPLC® 
BEH 
C18 
C18 Fully 
porous 
1.7 185 1 - 12 18000 80 60 Ethylene Bridged hybrid particle technology 
Universal column 
Wide variety of compounds 
Separations at high temperatures and extremes of pH 
Acquity 
UPLC® 
HSS T3 
Tri-
functionall
y 
bonded 
C18 ligand 
Fully 
porous 
1.8 230 2 - 8 18000 45 45 High strength silica particle technology 
High retention of polar organic analytes 
Balanced retention of hydrophilic and hydrophobic 
analytes 
Acquity 
UPLC® 
CSH 
C18 
C18 Fully 
porous 
1.7 185 1 - 11 18000 60 45 Charged surface hybrid particle technology 
Separation of basic analytes at low pHs 
Fast pH transitions and equilibration 
Fast method development 
CORTE
CS 
UPLC® 
C18 
C18 Solid core 1.6 100 2 - 8 18000 45 20 Solid-core particle technology 
High efficiency and increased sensitivity 
Normal 
phase 
Kinetex
® 
HILIC  
Unbonded 
silica 
(silanol 
groups) 
Solid core 
with 
a porous 
shell 
1.7 200 2 - 7.5 14500 60 < 60 Core-shell particle technology: 1.25 µm solid core with a 
0.23 µm porous coating 
Hydrophilic interaction chromatography 
High selectivity and increased retention of highly polar 
analytes 
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Table 3 
Analytical performance of the optimized MEPS/UHPLC-PDA methodology. 
Analytes IS 11PGF2α LTE4 LTB4 
Peak number - 1 2 3 
RTa (min) 7.43 7.65 9.61 10.75 
λmaxb (nm) 366 192 281 270 
LDRc (µg L-1) - 5 - 300 0.5 - 30 0.1 - 30 
Calibration in solvent        
Regression equation - y = 0.1304x + 0.6418 y = 0.1225x + 0.0627 y = 0.1708x + 0.0105 
r2d - 0.9988 0.9989 0.9997 
re - 0.9994 0.9995 0.9998 
Calibration in matrix         
Regression equation - y = 0.0951x - 2.6893 y = 0.0932x + 0.0224 y = 0.1385x - 0.0640 
r2d - 0.9841 0.9884 0.9989 
re - 0.9920 0.9942 0.9994 
Matrix effect (%) - 73 76 81 
Method limits         
LODf (µg L-1) - 1.12 0.16 0.04 
LOQg (µg L-1) - 2.11 0.35 0.10 
Lack-of-fit test         
Fcalculated:Ftabulatedh - 1.48:2.49h 0.67:2.49h 0.32:2.22i 
Goodness-of-fit test         
Fcalculated:Ftabulated - 0.00:2.49h 0.06:2.49h 0.11:2.22i 
Mandel's fitting test         
Fcalculated:Ftabulated - 2.50:7.71j 0.12:7.71j 0.08:5.99k 
a RT – retention time. 
b λmax – maximum absorbance values obtained in the PDA system detection. 
c LDR – linear dynamic range. 
d r2 – coefficient of determination. 
e r – coefficient of correlation (Person’s r). 
f LOD – limit of detection. 
g LOQ – limit of quantification. 
h Ftabulated – numerator degrees of freedom (df1) = 5; denominator degrees of freedom (df2) = 35; p = 95%. 
i Ftabulated – df1 = 7; df2 = 45; p = 95%. 
j Ftabulated – df1 = 1; df2 = 4; p = 95%. 
k Ftabulated – df1 = 1; df2 = 6; p = 95%. 
 
 
 
Table 4 
Precision, accuracy and extraction efficiency obtained for the 11β-prostaglandin F2α 
(11βPGF2), leukotriene E4 (LTE4) and leukotriene B4 (LTB4) at different levels of 
concentration. 
Analytes Precision (% RSD) 
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Level of 
concentrationa 
(µg L-1) 
Intraday 
repeatability 
(N = 12) 
Intermediate 
precision 
(N = 9) 
Accuracy 
(%) 
Extraction 
efficiency 
11βPGF2α LL 25 3.17 4.81 93.62 95.52 
  ML 100 3.17 3.89 100.50 99.71 
  HL 200 3.73 5.40 103.02 98.87 
LTE4 LL 2.5 6.63 10.43 96.73 91.13 
  ML 10 4.70 2.86 95.85 83.86 
  HL 20 3.11 1.29 103.51 74.99 
LTB4 LL 2.5 6.17 6.54 101.08 84.53 
  ML 10 4.82 3.57 96.32 92.25 
  HL 20 4.58 3.68 100.04 88.14 
a Levels of concentration in the validation studies: LL – low level, ML – medium level and HL – high 
level 
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Table 5 
Comparison the analytical performance of different methodologies reported in the literature for the analysis of urinary eicosanoids.  
Eicosanoid
s 
Extractio
n 
platform 
Extraction 
solvents 
(µL) 
Sampl
e 
volum
e (µL) 
Analytical 
platform 
Separation 
solvents 
Flow rate 
(µL min-
1) 
Time of 
analysis 
(min) 
Method limits 
(µg L-1) 
r2 Precision 
(% RSD) 
Accurac
y 
(%) 
Extractio
n 
efficiency 
(%) 
Ref. 
        LOD LO
Q 
 Intrada
y 
repeata
bility 
Interme
diate 
precisio
n 
   
LTB4 MEPS 350 (0.1% 
FA) and 
350 (ACN) 
2500 UHPLC-
PDA 
0.1% FA 
and ACN 
at 0.1% FA 
500 10 0.37 1.22 0.995 3.69 - 
20.19 
3.78 - 
20.37 
85.2 - 
104.3 
Not 
specified 
[24] 
LTB4, 
LTE4 and 
11βPGF2α 
MEPS 850 (0.1% 
FA), 750 
(ACN) and 
100 
(MeOH) 
2500 UHPLC-
PDA 
0.1% FA 
and ACN 
at 0.1% FA 
300 14 0.04 - 
1.12 
0.1 - 
2.11 
0.9988 
- 
0.9997 
3.11 - 
6.63 
1.29 - 
10.43 
93.62 - 
103.51 
74.99 - 
99.71 
This 
study 
LTE4 Not used Not used Not 
specifi
ed 
UHPLC-Q-
TOF/MS 
0.1% FA, 
20 mM 
ammonium 
formate 
and MeOH 
at 0.1% FA 
400 21 Not 
specified 
Not 
speci
fied 
0.9801 Not 
specifie
d 
Not 
specified 
Not 
specified 
Not 
specified 
[35] 
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PG 
metabolite
s, TXs, 
IsoPs and 
LTs 
SPE PGs, IsoPs 
and TXs: 
3000 
(MeOH), 
6000 (0.1% 
acetic 
acid), 3000 
(ACN) 
LTs: 4000 
(MeOH), 
6000 (0.1% 
acetic 
acid), 1000 
(50% 
MeOH) 
2000 - 
2700 
(dilute
d 
urine) 
UHPLC-
MS/MS 
PGs, IsoPs 
and TXs: 
0.1 % 
acetic acid 
and 
ACN:isopr
opanol 
(9:1, v/v) 
LTs: 0.2% 
FA and 
ACN/isopr
opanol 
(90:10) 
325 - 450 4.25 - 24 0.55 fmol 
(2,3-
dinor-8-
isoPGF2α
) to 15.4 
fmol 
(tetranorP
GEM) 
Not 
speci
fied 
linear 
from > 
27-
fold 
concen
tration 
range 
1.30 - 
34.8 
Not 
specified 
48.7 - 
118.2 
Not 
specified 
[10] 
PGs and 
IsoPs 
SPE Equilibratio
n with 
MeOH and 
water, 
elution 
with 80% 
MeOH (1% 
acetic 
acid). 
Volumes 
not 
specified. 
200 UHPLC-
MS/MS 
Water and 
MeOH:AC
N (1:1, v/v) 
200 20 Not 
specified 
All 
anal
ytes 
= 
0.05 
0.99 0.92 - 
16.59 
0.90 - 
9.12 
87.98 - 
119.46 
Not 
specified 
[36] 
tetranor-
PG, IsoPs; 
Txs, LTE4, 
12-HETE 
LLE 11250 
(MeOH:chl
oroform, 
2:1, v/v) 
and 3750 
(chlorofor
m) 
3000 HPLC-
MS/MS 
0.1% FA 
and ACN 
at 0.1% FA 
600 14 0.002 - 
0.06 
0.00
6 - 
0.18 
0.996 - 
0.999 
1.08 - 
11.20 
2.70 - 
11.5 
94.9 - 
112.9 
25.00 - 
100.00 
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HETEs, 
EETs, 
oxoETEs, 
HODEs, 
PGs, 
oxoODE 
LLE 1000 (10% 
acetic 
acid:2-
propanol:he
xane, 
2:20:30, 
v/v/v) 6000 
(hexane),  
200 HPLC-
MS/MS 
0.2% acetic 
acid and 
MeOH 
200 32 2.6 - 64 
pg 
0.09 
- 2.2 
Not 
specifi
ed 
3.40 - 
14.00 
5.3 - 
10.9 
100.02 - 
109.60 
10 - >85 [38] 
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